1:00pm to 2:00pm |
|
Risks of Pegylated Interferon Therapies for HCV Infections in Patients with Cirrhosis
(VTC)
John M. Vierling, MD
Professor, Medicine and Surgery
Chief of Hepatology
Director, Baylor Liver Health
Director, Advanced Liver Therapies
Baylor College of Medicine
St. Luke's Episcopal Hospital
Houston, Texas
More than three million people in the United States are believed to have chronic hepatitis C virus infection. In this seminar, Dr. Vierling will discuss up-to-date data on the efficacy of non-interferon antiviral therapies for hepatitis C infection.
Hosted by: Michael J. Friedlander, PhD, Executive Director, Virginia Tech Carilion Research Institute More information...
|